← April 8, 2026 briefingHealth
Telehealth abortion access preserved pending FDA review
A federal judge has ruled that mifepristone must undergo an FDA safety review before Louisiana's attempt to ban its prescription via telemedicine can proceed, keeping telehealth abortion services available for now. The case is among the most consequential legal battles over medication abortion access since the fall of Roe, and the review timeline will determine how long the current access window stays open. Louisiana had sought to immediately block the use of mifepristone through telehealth providers.
Sources
